Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee
Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee
Pharmaceuticals

Hong Kong’s cancer DNA tests industry gets a boost as Taiwanese provider ACT Genomics opens lab

  • Taiwan-based ACT Genomics opens a HK$20 million laboratory at the Science Park in Sha Tin to process cancer patients’ samples
  • The five-year-old firm, based in Taipei, aims to build a regional network of self-operated and joint venture labs

Topic |   Pharmaceuticals
Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee
Dr Chen Hua Chien, chief executive officer at ACT Genomics, at the new Hong Kong laboratory at the science park in Sha Tin. Photo: Dickson Lee
READ FULL ARTICLE